UK Lawmakers Warn British Agreements with Donald Trump are 'Built on Sand'.

Government ministers and leading parliamentarians have raised concerns that the United Kingdom's recent agreements with the US administration are "built on sand." This follows revelations that a much-touted deal on pharmaceutical tariffs, which pledges zero tariffs in exchange for the NHS facing higher prices, lacks any formal legal text beyond limited headline terms outlined by government press releases.

An Agreement in Principle Only

The US-UK pharmaceuticals agreement, described as a "generational" achievement, exists as an "statement of intent" without a signed legal text. Critics have noted that the press releases from the UK and US governments frame the deal in sharply different terms. The British version emphasizes securing "zero per cent tariffs" as a singular success, while the American announcement dwells on the agreement for the NHS to pay 25% more for new medications.

"We face a genuine possibility that the UK government has made commitments to raise drug prices in return for only a pledge from President Trump," stated David Henig, a trade expert. "We know he has a record of not honouring his word."

Broader Instability and a Paused Tech Deal

Worries have been heightened by Washington's move to put on ice the £31bn "tech prosperity deal", which was previously called "a huge leap forward" in the bilateral relationship. The US claimed a lack of progress from the UK on reducing other tariffs as the reason for the pause.

Additionally, concessions secured for British farmers as part of an May trade agreement have yet to be formally ratified by the US, despite a imminent January deadline. "Our understanding is that the US has not finalized the reciprocal tariff rate quota," said Tom Bradshaw of the National Farmers' Union.

Anxiety Behind Closed Doors

Behind the scenes, ministers have admitted unease that the government's deals with Washington are lacking substance. One minister was quoted as stating the series of agreements as "built on sand," while another framed the situation as the "new normal" in the transatlantic relationship, marked by "greater risk and fluctuation."

Layla Moran, a senior MP on the health committee, stated: "The only thing more surprising than the US approach is the UK government's naive belief that his administration is a trustworthy negotiator. The NHS is of vital importance."

Official Reassurances and Concrete Outcomes

Ministry sources have downplayed the possibility of the US reneging on the pharmaceuticals deal. One source noted the US pharmaceutical industry itself had been lobbying for the agreement, seeking certainty on imports and pricing, making it of tangible value than the paused tech deal.

Officials acknowledge that instability is part and parcel of dealing with the Trump administration. However, they argue that the UK has obtained tangible results for businesses, such as reduced duties on automobiles compared to other nations. "Our achievement of 25% steel tariffs, which is better than the rate for the rest of the world, is a solid gain," one official said.

Nevertheless, problems have arisen in enacting the initial US-UK accord. Promised quotas on beef exports have yet to be finalized, and the commitment to "eliminate duties on UK metals" has remains unmet, with tariffs fixed at 25%.

Moving forward, the two sides have planned to recommence talks on the suspended digital agreement in January, following what were described as "very positive" meetings between UK and US officials in Washington.